Drug Price-Control Advocates Press CMS To Weigh March-In Alternatives For Xtandi

By Maaisha Osman / April 9, 2024 at 6:01 PM
Drug price-control advocates, frustrated by the government’s refusal so far to use march-in rights to lower drug prices, are trying a new tack: They are demanding CMS leverage the authority it used to provide free Moderna mRNA COVID-19 vaccine during the pandemic as a tool to now lower the cost of the expensive prostate cancer drug Xtandi. That authority allows the government to gain royalty free rights to a drug and license patents to generic drug makers without requiring evidence...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.